Clinical and demographical characteristics in a cohort of MND patients treated with riluzole. Differences between tablets and oral suspension

References

• Al-Chalabi A, Hardiman O, Kiernan MC, Chiò A, Rix-Brooks B, van den Berg LH. Amyotrophic lateral sclerosis: moving towards a new classification system. Lancet Neurol 2016;15:1182–94. Available at:
   PubMed Web of Science ®Google Scholar
• Barceló MA, Povedano M, Vázquez-Costa JF, Franquet Á, Solans M, Saez M. Estimation of the prevalence and incidence of motor neuron diseases in two Spanish regions: Catalonia and Valencia. Sci Rep [Internet] 2021;11:1–15. Available at:
   PubMed Web of Science ®Google Scholar
• Chio A, Calvo A, Moglia C, Mazzini L, Mora G, PARALS study group. Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study. J Neurol Neurosurg Psychiatry. 2011;82:740–6. Available at: 10.1136/jnnp.2010.235952
   PubMed Web of Science ®Google Scholar
• Tard C, Defebvre L, Moreau C, Devos D, Danel-Brunaud V. Clinical features of amyotrophic lateral sclerosis and their prognostic value. Rev Neurol (Paris) 2017;173:263–72. Available at: https://linkinghub.elsevier.com/retrieve/pii/S0035378716302880
   PubMed Web of Science ®Google Scholar
• Chiò A, Logroscino G, Hardiman O, Swingler R, Mitchell D, Beghi E, et al. Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler. 2009;10:310–23. Available at: 10.3109/17482960802566824
   PubMed Web of Science ®Google Scholar
• Gordon PH, Cheng B, Katz IB, Mitsumoto H, Rowland LP. Clinical features that distinguish PLS, upper motor neuron-dominant ALS, and typical ALS. Neurology 2009;72:1948–52.
   PubMed Web of Science ®Google Scholar
• Chio A, Mora G, Leone M, Mazzini L, Cocito D, Giordana MT, et al. Early symptom progression rate is related to ALS outcome: a prospective population-based study. Neurology [Internet]. 2002;59:99–103. Available at: 10.1212/WNL.59.1.99
   PubMed Web of Science ®Google Scholar
• Georgoulopoulou E, Fini N, Vinceti M, Monelli M, Vacondio P, Bianconi G, et al. The impact of clinical factors, riluzole and therapeutic interventions on ALS survival: a population based study in Modena, Italy. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14:338–45. Available at: 10.3109/21678421.2013.763281
   PubMed Web of Science ®Google Scholar
• Rowland LP, Shneider NA. Amyotrophic lateral sclerosis. N Engl J Med [Internet]. 2001;344:1688–700. Available at: www.nejm.org
   PubMed Web of Science ®Google Scholar
• Gargiulo-Monachelli GM, Janota F, Bettini M, Shoesmith CL, Strong MJ, Sica REP. Regional spread pattern predicts survival in patients with sporadic amyotrophic lateral sclerosis. Eur J Neurol. 2012;19:834–41. Available at: 10.1111/j.1468-1331.2011.03616.x
   PubMed Web of Science ®Google Scholar
• Van Der Kleij LA, Jones AR, Steen IN, Young CA, Shaw PJ, Shaw CE, et al. Regionality of disease progression predicts prognosis in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Front Degener [Internet]. 2015;16:442–7. Available at: http://www.tandfonline.com/action/journalInformation?journalCode=iafd20
   PubMed Web of Science ®Google Scholar
• Gonzalez Calzada N, Prats Soro E, Mateu Gomez L, Giro Bulta E, Cordoba Izquierdo A, Povedano Panades M, et al. Factors predicting survival in amyotrophic lateral sclerosis patients on non-invasive ventilation. Amyotroph Lateral Scler Frontotemporal Degener. 2016;17:337–42. Available at: 10.3109/21678421.2016.1165256. Accessed July 1, 2016.
   PubMed Web of Science ®Google Scholar
• Audag N, Goubau C, Toussaint M, Reychler G. Screening and evaluation tools of dysphagia in adults with neuromuscular diseases: a systematic review. Ther Adv Chronic Dis. 2019;10:2040622318821622. Available at: 10.1177/2040622318821622
   Web of Science ®Google Scholar
• Fattori B, Siciliano G, Mancini V, Bastiani L, Bongioanni P, Caldarazzo Ienco E, et al. Dysphagia in amyotrophic lateral sclerosis: relationships between disease progression and fiberoptic endoscopic evaluation of swallowing. Auris Nasus Larynx 2017;44:306–12. Available at: https://linkinghub.elsevier.com/retrieve/pii/S0385814616302024
   PubMed Web of Science ®Google Scholar
• Ruoppolo G, Schettino I, Frasca V, Giacomelli E, Prosperini L, Cambieri C, et al. Dysphagia in amyotrophic lateral sclerosis: prevalence and clinical findings. Acta Neurol Scand. 2013; 128:397–401. Available at: 10.1111/ane.12136
   PubMed Web of Science ®Google Scholar
• da Costa Franceschini A, Mourão LF. Dysarthria and dysphagia in amyotrophic lateral sclerosis with spinal onset: a study of quality of life related to swallowing. Brogårdh C, Lexell J, editors. NeuroRehabilitation [Internet]. 2015; 36:127–34. Available at: 10.3233/NRE-141200
   PubMed Web of Science ®Google Scholar
• Romero-Gangonells E, Virgili-Casas MN, Dominguez-Rubio R, Povedano M, Pérez-Saborit N, Barceló MA, et al. Evaluation of dysphagia in motor neuron disease. Review of available diagnostic tools and new perspectives. Dysphagia [Internet]. 2021;36:558–73. Available at: 10.1007/s00455-020-10170-7
   PubMed Web of Science ®Google Scholar
• Knuijt S, Kalf JG, de Swart BJM, Drost G, Hendricks HT, Geurts ACH, et al. Dysarthria and dysphagia are highly prevalent among various types of neuromuscular diseases. Disabil Rehabil. 2014;36:1285–9. Available at: 10.3109/09638288.2013.845255
   PubMed Web of Science ®Google Scholar
• Onesti E, Schettino I, Gori MC, Frasca V, Ceccanti M, Cambieri C, et al. Dysphagia in amyotrophic lateral sclerosis: impact on patient behavior, diet adaptation, and riluzole management. Front Neurol [Internet] 2017;8:94. Available at: http://www.ncbi.nlm.nih.gov/pubmed/28377742
   PubMed Web of Science ®Google Scholar
• Miller RG, Jackson CE, Kasarskis EJ, England JD, Forshew D, Johnston W, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology [Internet] 2009;73:1218–26. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2764727&tool=pmcentrez&rendertype=abstract. Accessed August 10, 2015.
   PubMed Web of Science ®Google Scholar
• Vergonjeanne M, Fayemendy P, Marin B, Penoty M, Lautrette G, Sourisseau H, et al. Predictive factors for gastrostomy at time of diagnosis and impact on survival in patients with amyotrophic lateral sclerosis. Clin Nutr 2020;39:3112–8. Available at: https://linkinghub.elsevier.com/retrieve/pii/S0261561420300418
   PubMed Web of Science ®Google Scholar
• Wright DJ, Smithard DG, Griffith R. Optimising Medicines Administration for Patients with Dysphagia in Hospital: Medical or Nursing Responsibility? Geriatrics [Internet] 2020;5:9. Available at: https://www.mdpi.com/2308-3417/5/1/9
   PubMed Web of Science ®Google Scholar
• Wright D, Chapman N, Foundling-Miah M, Greenwall R, Griffith R, Guyon A, et al. Guideline on the medication management of adults with swallowing difficulties. Guidelines in Practice 2015;11. Available at: https://www.rosemontpharma.com/sites/default/files/20150911_adult_dysphagia_full_guideline_clean_approved_sept_15.pdf
   Google Scholar
• Introna A, D'Errico E, Modugno B, Scarafino A, Fraddosio A, Distaso E, et al. Adherence to riluzole in patients with amyotrophic lateral sclerosis: an observational study. Neuropsychiatr Dis Treat 2018;14:193–203. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5757977/pdf/ndt-14-193.pdf
   PubMed Web of Science ®Google Scholar
• Dharmadasa T, Kiernan MC. Riluzole, disease stage and survival in ALS. Lancet Neurol [Internet] 2018;17:385–6. Available at:
   PubMed Web of Science ®Google Scholar
• Fang T, Al Khleifat A, Meurgey J-H, Jones A, Leigh PN, Bensimon G, et al. Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study. Lancet Neurol 2018;17:416–22. Available at: https://linkinghub.elsevier.com/retrieve/pii/S1474442218300541
   PubMed Web of Science ®Google Scholar
• Zoccolella S, Beghi E, Palagano G, Fraddosio A, Guerra V, Samarelli V, et al. Riluzole and amyotrophic lateral sclerosis survival: a population-based study in southern Italy. Eur J Neurol. 2007;14:262–8. Available at: 10.1111/j.1468-1331.2006.01575.x
   PubMed Web of Science ®Google Scholar
• Dyer AM, Smith A. Riluzole 5 mg/mL oral suspension: for optimized drug delivery in amyotrophic lateral sclerosis. Drug Des Devel Ther 2017;11:59–64. Available at: https://www.dovepress.com/riluzole-5-mgml-oral-suspension-for-optimized-drug-delivery-in-amyotro-peer-reviewed-article-DDDT
   PubMed Web of Science ®Google Scholar
• Povedano Panades M, Couratier P, Sidle K, Sorarù G, Tsivgoulis G, Ludolph AC. Administration of riluzole oral suspension during the different stages of amyotrophic lateral sclerosis. Front Neurol [Internet] 2021;12:10–3. Available at: 10.3389/fneur.2021.633854/full
   Web of Science ®Google Scholar
• Brooks BR, Bettica P, Cazzaniga S. Riluzole oral suspension: bioavailability following percutaneous gastrostomy tube-modeled administration versus direct oral administration. Clin Ther [Internet] 2019;41:2490–9. Available at:
   PubMed Web of Science ®Google Scholar
• Miller RG, Mitchell JD, Lyon M, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). In: Miller RG, ed. Cochrane database of systematic reviews [Internet]. Chichester, UK: John Wiley & Sons, Ltd; 2007. Available at: 10.1002/14651858.CD001447.pub2
   Google Scholar
• Andrews JA, Jackson CE, Heiman-Patterson TD, Bettica P, Brooks BR, Pioro EP. Real-world evidence of riluzole effectiveness in treating amyotrophic lateral sclerosis. Amyotroph Lateral Scler Front Degener [Internet]. 2020;21:509–18. Available at:
   PubMed Web of Science ®Google Scholar
• Knibb JA, Keren N, Kulka A, Leigh PN, Martin S, Shaw CE, et al. A clinical tool for predicting survival in ALS. J Neurol Neurosurg Psychiatry. 2016;87:1361–7. Available at: 10.1136/jnnp-2015-312908
   PubMed Web of Science ®Google Scholar
• Brooks BR. El escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. J Neurol Sci [Internet] 1994;124:96–107. Available at: http://www.ncbi.nlm.nih.gov/pubmed/7807156
   PubMed Web of Science ®Google Scholar
• Ludolph A, Drory V, Hardiman O, Nakano I, Ravits J, Robberecht W, et al. A revision of the El Escorial criteria - 2015. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16:291–2. Available at: 10.3109/21678421.2015.1049183
   PubMed Web of Science ®Google Scholar
• Turner MR, Talbot K. Primary lateral sclerosis: diagnosis and management. Pract Neurol. 2020;20:262–9. Available at: 10.1136/practneurol-2019-002300
   PubMedGoogle Scholar
• Wijesekera LC, Mathers S, Talman P, Galtrey C, Parkinson MH, Ganesalingam J, et al. Natural history and clinical features of the flail arm and flail leg ALS variants. Neurology [Internet]. 2009;72:1087–94. Available at: 10.1212/01.wnl.0000345041.83406.a2
   PubMed Web of Science ®Google Scholar
• Chiò A, Moglia C, Canosa A, Manera U, D'Ovidio F, Vasta R, et al. ALS phenotype is influenced by age, sex, and genetics. Neurology [Internet]. 2020;94:e802–10–e810. Available at: 10.1212/WNL.0000000000008869
   Web of Science ®Google Scholar
• Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data [Internet]. In: Prentice RL, ed. The statistical analysis of failure time data. Hoboken, NJ: John Wiley & Sons, Inc.; 2002:1–439. (Wiley Series in Probability and Statistics). Available at: 10.1002/9781118032985
   Google Scholar
• Harrington DP, Fleming TR. A class of rank test procedures for censored survival data. Biometrika [Internet] 1982;69:553–66. Available at: 10.1093/biomet/69.3.553
   Web of Science ®Google Scholar
• Wolf J, Safer A, Wöhrle JC, Palm F, Nix W. a, Maschke M, et al. Variability and prognostic relevance of different phenotypes in amyotrophic lateral sclerosis—data from a population-based registry. J Neurol Sci. 2014;345:164–7. Available at: https://linkinghub.elsevier.com/retrieve/pii/S0022510X14004791
   PubMed Web of Science ®Google Scholar
• Benbrika S, Desgranges B, Eustache F, Viader F. Cognitive, emotional and psychological manifestations in amyotrophic lateral sclerosis at baseline and overtime: a review. Front Neurosci 2019;13:951–22. Available at: 10.3389/fnins.2019.00951/full
   PubMed Web of Science ®Google Scholar
• Andersen PM, Borasio GD, Dengler R, Hardiman O, Kollewe K, Leigh PN, et al. Good practice in the management of amyotrophic lateral sclerosis: clinical guidelines. An evidence‐based review with good practice points. EALSC Working Group. Amyotroph Lateral Scler. 2007;8:195–213. Available at: 10.1080/17482960701262376
   PubMed Web of Science ®Google Scholar
• Raymond J, Oskarsson B, Mehta P, Horton K. Clinical characteristics of a large cohort of US participants enrolled in the National Amyotrophic Lateral Sclerosis (ALS) Registry, 2010–2015. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20:413–20. Available at: 10.1080/21678421.2019.1612435
   PubMed Web of Science ®Google Scholar
• Fasano A, Fini N, Ferraro D, Ferri L, Vinceti M, Mandrioli J. Percutaneous endoscopic gastrostomy, body weight loss and survival in amyotrophic lateral sclerosis: a population-based registry study. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18:233–42. Available at: 10.1080/21678421.2016.1270325
   PubMed Web of Science ®Google Scholar
• Mandrioli J, Malerba SA, Beghi E, Fini N, Fasano A, Zucchi E, et al. Riluzole and other prognostic factors in ALS: a population-based registry study in Italy. J Neurol. 2018;265:817–27. Available at: 10.1007/s00415-018-8778-y
   PubMed Web of Science ®Google Scholar
• Belissa E, Vallet T, Laribe-Caget S, Chevallier A, Chedhomme F-X, Abdallah F, et al. Acceptability of oral liquid pharmaceutical products in older adults: palatability and swallowability issues. BMC Geriatr. 2019;19:344. Available at: 10.1186/s12877-019-1337-2
   PubMed Web of Science ®Google Scholar
• Liu F, Ghaffur A, Bains J, Hamdy S. Acceptability of oral solid medicines in older adults with and without dysphagia: a nested pilot validation questionnaire based observational study. Int J Pharm [Internet] 2016;512:374–81. Available at:
   PubMed Web of Science ®Google Scholar